AXIM shifts COVID-19 NAb test to RUO; separates from Empowered Diagnostics

AXIM BIOTECHNOLOGIES, INC.

COVID-19 NAb test now offered For Research Use Only after FDA changed priorities from qualitative testing.
Entered separation agreement with Empowered Diagnostics, LLC following FDA recall of their products.
Two RUO tests available: quantitative (exact number) and semi-quantitative (high/medium/low titers).
Partner Dr. Lake conducting ongoing correlative study at ASU on vaccine vs natural immunity NAb levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.